Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

8

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

A673

8

DNA topoisomerase II

8

DNA topoisomerase II alpha

8

HepG2

8

Human ovarian cancer cell line

8

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

8

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1974

8

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

AIDS-related Kaposi’s sarcoma

8

Glioblastoma

8

Kaposi’s sarcoma

8

Locally advanced or unresectable soft tissue sarcoma

8

Metastatic non-small cell lung cancer

8

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

8

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

The Regents of The University of Colorado

8

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

8

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

8

FDA UNII

8

NCI_THESAURUS

8

PUBCHEM

8

DRUG BANK

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Anthracyclines and related substances

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DOXORUBICIN

80168379AG

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

Conditions:

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and in...

hibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

AVA-6000

7XPB9B6MUA

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

Conditions:

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and in...

hibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

ZOPTARELIN DOXORUBICIN ACETATE

4IA03SIO30

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

Conditions:

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and in...

hibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

DOXORUBICIN CITRATE

AJQ2ZNG2WL

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

Conditions:

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and in...

hibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

ALDOXORUBICIN HYDROCHLORIDE

S098K6HGD9

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

Conditions:

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and in...

hibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

ALDOXORUBICIN

C28MV4IM0B

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

Conditions:

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and in...

hibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

ZOPTARELIN DOXORUBICIN

27844X2J29

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

Conditions:

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and in...

hibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

DOXORUBICIN HYDROCHLORIDE

82F2G7BL4E

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

Conditions:

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and in...

hibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1